Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia. (3rd August 2018)

• Record Type: Journal Article
• Authors: Kellner, Christian; Peipp, Matthias; Gramatzki, Martin; Schrappe, Martin; Schewe, Denis M.
• Is Part Of: Oncoimmunology. Volume 7:Number 8(2018)
• Publication Date: 2018-08-03
• Subjects: Acute lymphoblastic leukemia -- bispecific antibodies -- CAR T cells -- CD19 -- Fc engineering; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2018.1448331
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential. In light of recent preclinical and clinical data, perspectives of such antibodies designed for improved effectiveness in BCP-ALL are presented.